Protea Biosciences (PRGB) 0.4800 $PRGB Protea to acquire

Protea Biosciences (PRGB) 0.4800 $PRGB

Protea to acquire vivoPharm and intends to develop and market new services for pharmaceutical R&D
M2 - Tue Apr 07, 7:19AM CDT
Molecular information company Protea Biosciences Group (OTCBBRGB) on Tuesday disclosed that it has entered into an agreement to acquire vivoPharm Pty for an undisclosed amount.

Protea Bio buys biopharma services firm
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 7:00AM CDT


Protea Announces Agreement to Acquire vivoPharm
GlobeNewswire - Tue Apr 07, 6:30AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that it has entered into an agreement dated as of March 31, 2015 for the purchase of vivoPharm Pty Ltd. ("vivoPharm", a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models.

IPOs & Transactions Week in Review: February 9 - 13 / plus free S-1 workflow whitepaper
PR Newswire - Mon Feb 16, 11:21AM CST
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.
VUZI: 6.74 (+1.03)

Purdue acquires LAESI Technology from Protea for herbicide research applications
M2 - Fri Jan 16, 7:31AM CST
Molecular information company Protea Biosciences Group (OTC BBRGB) disclosed on Thursday the sale of its LAESI DP-1000 Instrument System to Purdue University for an undisclosed amount.

Purdue Acquires Protea's LAESI(R) Technology
GlobeNewswire - Thu Jan 15, 7:59AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that Purdue University has acquired Protea's LAESI DP-1000 Instrument System for direct molecular analysis. The system will be used in Purdue's College of Agriculture, the Department of Botany and Plant Pathology, for the molecular imaging of herbicide active ingredients and other related compounds to optimize herbicide applications and improve weed management.

Protea Launches New Tissue Analytics Software and Workflow
GlobeNewswire - Mon Jan 12, 10:16AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that it has developed a new software platform, known as "Histology Guided Mass Spec Imaging (HG-MSI)", that enables pathologists to combine traditional microscopy and histology with high resolution mass spectrometry molecular imaging. The Company made the announcement today while presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA along with the J.P. Morgan 33 Annual Healthcare Conference.

Protea Biosciences to Present at Biotech Showcase(TM) 2015
GlobeNewswire - Wed Jan 07, 7:30AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea", "the Company" announced today that Stephen Turner, CEO and Chairman, will be presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA.

Protea Biosciences to Present at LD Micro Conference
GlobeNewswire - Tue Dec 02, 7:30AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea", "the Company" announced today that its CEO and Chairman, Stephen Turner, will present at the 7 annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 1:00 p.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, California.

Protea Biosciences Announces 2014 Third Quarter Financial Results
GlobeNewswire - Tue Nov 18, 8:00AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" or the "Company" announced today that it has reported financial results for its third quarter ended September 30, 2014. Gross revenue in the third quarter of 2014 totaled $517,569, a 190% increase compared to the third quarter of 2013 and the highest revenue for any quarter in the Company's history. Gross revenue for the nine months ended September 30, 2014 totaled $1,332,230, compared to $938,080 for the same period of 2013, representing a 42% increase. The Company's two core lines of business, molecular information services and LAESI instrument platforms, showed greater than 200% increases in gross revenues for the third quarter period over the same period in 2013.

Protea Biosciences Releases Mass Spectrometry Imaging Data for Characterizing 3D Microtissues
GlobeNewswire - Thu Nov 06, 7:43AM CST
Protea Biosciences Group, Inc. (OTCQBRGB) announced today that is has released the presentation titled, "Mass spectrometry imaging for the characterization of 3D microtissues," which was presented by Dr. Erin Seeley of Protea at the InSphero AG user group meeting held in San Francisco, California on October 24, 2014. The presentation can be found through the following link.

Protea Biosciences Group divests LAESI DP-1000 Instrument System to Princeton University
M2 - Thu Oct 16, 5:28AM CDT
Molecular information company Protea Biosciences Group (OTC BBRGB) revealed on Wednesday the sale of its LAESI DP-1000 Instrument System for direct molecular analysis to Princeton University.

Princeton University Acquires Protea's LAESI(R) Technology Platform
GlobeNewswire - Wed Oct 15, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that Princeton University has purchased Protea's LAESI DP-1000 Instrument System for direct molecular analysis. The system will be used in Princeton's Frick Chemistry Laboratory for the screening of microbial samples to identify new molecular entities that may hold promise as new antimicrobial therapeutics.

Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues
PRWeb - Thu Oct 02, 7:46AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) and InSphero AG jointly announced today an update from their collaboration focused on mass spectrometry imaging of InSphero's 3D InSight™ microtissues. In August 2014, Protea received microtissues from InSphero and hosted members of InSphero's scientific team for onsite training on the handling and preparation of the microtissues. Protea has since developed workflows for processing the 3D microtissues for mass spectrometry imaging and direct analysis. In addition, Protea has generated data from 3D microtissues grown from the HCT-116 colon cancer cell line that showed the ability for mass spectrometry imaging to detect and image numerous native proteins in 3D microtissues in a single experiment, as well as putatively identify several proteins known to be present at elevated levels in colon cancer cells. Erin Seeley, PhD, Protea's Senior Scientist for Mass Spectrometry Imaging, will present the first data from Protea and InSphero's collaboration at InSphero's upcoming User Group Meetings being held in San Francisco, California on Friday, October 24th, 2014 and in Boston, Massachusetts on Thursday, November 20th, 2014. Information about the User Group Meetings can be found in the links below:

USDA Acquires Protea's LAESI(R) Technology Platform
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that the United States Department of Agriculture (USDA) Agricultural Research Service has purchased Protea's LAESI DP-1000 System for direct molecular analysis. The system will be used by the USDA to identify and screen for mycotoxins in food and feed that can be hazardous to humans and animals.

Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies
GlobeNewswire - Wed Jul 09, 7:30AM CDT
Protea to Apply Direct 3D Molecular Imaging Platform to InSphero's 3D InSight(TM) Microtissues

Protea Announces Presence at 62nd American Society of Mass Spectrometry Annual Conference June 15 - 19, 2014 at the Baltimore Convention Center
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Protea Biosciences Group, Inc. (OTCQBRGB) ("Protea" announced today that it will be attending the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center, located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15 through Thursday June 19.